Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
CLARITHROMYCIN
Abbott Laboratories Ireland Ltd
CLARITHROMYCIN
500 Milligram
Modified-release Tablets
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
PATIENT INFORMATION LEAFLET ON KLACID LA 500 MG MODIFIED RELEASE TABLETS (CLARITHROMYCIN) PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist This medicine has been prescribed to you. Do not pass it to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Klacid LA is and what it is used for 2. Before you take Klacid LA 3. How to take Klacid LA 4. Possible side effects 5. How to store Klacid LA 6. Further information 1. WHAT KLACID LA IS AND WHAT IT IS USED FOR Klacid LA is an antibiotic belonging to a group called the macrolides. Antibiotics stop the growth of certain germs that cause infections. Its use is described below. Klacid LA tablets are modified release tablets which means that the active ingredient is released slowly from the tablet so that you only have to take the medicine once a day. WHAT ARE KLACID LA TABLETS USED FOR? The Klacid LA tablets are used to treat infections such as: 1. Chest infections such as bronchitis and pneumonia 2. Throat and sinus infections 3. Skin and soft tissue infections, which may also be called cellulitis, folliculitis or erysipelas. Klacid LA Tablets are used in adults and children 12 years and older. 2. BEFORE YOU TAKE KLACID LA DO NOT TAKE KLACID LA TABLETS If you know that you are allergic to clarithromycin or other antibiotics from the same drug class (macrolide antibiotics) such as erythromycin or azithromycin. If you are taking ergotamine or dihydroergotamine tablets Citiți documentul complet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Klacid LA 500mg Modified release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Clarithromycin 500 mg Each tablet contains 115 mg lactose Each tablet contains 15.3 mg sodium _For full list of excipients, see section 6.1._ 3 PHARMACEUTICAL FORM Modified release tablet. Yellow, ovaloid modified-release tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Klacid LA is indicated for treatment of infections caused by susceptible organisms. Indications include: Lower respiratory tract infections for example bronchitis and pneumonia. Upper respiratory tract infections for example sinusitis and pharyngitis. Skin and soft tissue infections for example folliculitis, cellulitis and erysipelas. As with other antibiotics, it is recommended that guidelines on the prevalence of local resistance, and associated medical practice regarding theprescription of antibiotics, be consulted before prescribing Klacid LA. Klacid LA is indicated in adults and children 12 years and older. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS: The usual recommended dosage of Klacid LA in adults is one 500 mg modified -release tablet daily to be taken with food. In more severe infections, the dosage can be increased to two 500 mg modified-release tablets taken as one dose daily. Dose must be taken at the same time every day. Tablets must be swallowed whole. The usual duration of treatment is 6 to 14 days. CHILDREN OLDER THAN 12 YEARS: As for adults. CHILDREN YOUNGER THAN 12 YEARS: The use of Klacid LA has not been studied in children less than 12 years of age. Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Use of Klacid LA is not recommended Citiți documentul complet